Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KIMBERLY CLARK CORPKMB · Entity 3103 | Director | January 02, 2026 | January 05, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | President, Human Health Int?l | January 26, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KIMBERLY CLARK CORP
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,701 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 1,923 · Balance 3,701 F1: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F2: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors.
F2: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock.
Merck & Co., Inc.
Report date January 26, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,739.343 |
Reported balance
After 2026-01-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 5,703 · Balance 28,739.343 F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025.
F2: Holdings include shares acquired in dividend reinvestment transactions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 28, 2026 21:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 5,703 | $107.40 | $612,502.20 |
DisclosureSEC source: 0000310158-26-000022 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,739.343 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:22 UTC | KIMBERLY CLARK CORP KMB · Entity 3103 | GrantRestricted Share Units · Derivative | 1,923 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-000221 · doc4.xml · derivative · entry 1 Romanelli Joseph · CIK 0001938322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,701 Underlying: Common Stock · 1,923 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.exercise_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.expiration_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's common stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F2 · balance_after: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · derivative · entry 6 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,262 Underlying: Common Stock · 2,262 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,115 | $83.26 | $92,834.90 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,945.545 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,262 | $83.26 | $188,334.12 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060.545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · derivative · entry 5 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,128 Underlying: Common Stock · 2,063 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,017 | $84.71 | $86,150.07 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,798.545 Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,063 | $84.71 | $174,756.73 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,815.545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 21,494 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,494 Underlying: Common Stock · 21,494 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 9,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,444 Underlying: Common Stock · 9,444 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 Underlying: Common Stock · 4,722 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:38 UTC | KIMBERLY CLARK CORP KMB · Entity 3103 | GrantRestricted Share Units · Derivative | 1,493 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000361 · doc4.xml · derivative · entry 1 Romanelli Joseph · CIK 0001938322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,726 Underlying: Common Stock · 1,493 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.exercise_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.expiration_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F2 · balance_after: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 19:15 UTC | KIMBERLY CLARK CORP KMB · Entity 3103 | GrantRestricted Share Units · Derivative | 233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-009926 · doc4.xml · derivative · entry 1 Romanelli Joseph · CIK 0001938322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233 Underlying: Common Stock · 233 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · price: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.exercise_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F1 · derivative.expiration_date: Represents restricted share units, payable on a 1-for-1 basis, granted under the Kimberly-Clark Corporation Outside Directors' Compensation Plan. Additional restricted share units are accrued based on dividends paid on the Corporation's Common Stock. The restricted share units may not be sold or transferred until the reporting person ceases to be a member of the Corporation's Board of Directors. F2 · balance_after: Includes restricted share units which were accrued based on dividends paid on the Corporation's common stock. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 5 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,524 Underlying: Common Stock · 2,262 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 1,115 | $128.80 | $143,612.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,716.325 Read SEC document |
| May 02, 2024 Filed May 2, 2024 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 2,262 | $128.80 | $291,345.60 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,831.325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 23,438 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,438 Underlying: Common Stock · 23,438 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:29 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 6,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013994 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,191 Underlying: Common Stock · 6,191 shares Expires 2027-04-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 21:03 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 1,000 | $124.89 | $124,887.90 |
DisclosureSEC source: 0001127602-24-004993 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,569.325 Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 59 | $107.37 | $6,334.89 |
DisclosureSEC source: 0001127602-23-021936 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 Read SEC document |
| August 02, 2023 Filed Aug 3, 2023 20:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 30 | $107.37 | $3,221.13 |
DisclosureSEC source: 0001127602-23-021936 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,569.325 Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 6,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014547 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,786 Underlying: Common Stock · 6,786 shares Expires 2026-05-02 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 23,513 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014547 · form4.xml · derivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,513 Underlying: Common Stock · 23,513 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| April 26, 2023 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 3 | $113.68 | $341.04 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 9 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,599.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| March 24, 2023 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 35 | $104.65 | $3,662.75 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 8 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,596.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| March 20, 2023 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 136 | $105.47 | $14,343.92 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 7 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,631.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| February 21, 2023 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 11 | $109.20 | $1,201.20 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 6 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,495.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 16:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 5,000 | $108.22 | $541,100.50 |
DisclosureSEC source: 0001127602-23-005484 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,284.325 Read SEC document |
| December 19, 2022 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 7 | $109.04 | $763.28 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 5 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,484.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 13, 2022 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 56 | $110.96 | $6,213.76 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,477.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 06, 2022 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 30 | $109.39 | $3,281.70 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,421.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 05, 2022 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 107 | $109.54 | $11,720.78 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,391.325 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
| December 02, 2022 Filed Jun 30, 2023 20:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | PurchaseCommon Stock | 59 | $109.67 | $6,470.53 |
DisclosureSEC source: 0001127602-23-019612 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 59 F1 · shares: None of the purchases or sales reported herein were directed by the reporting person, but were executed by a brokerage firm for the benefit of the reporting person's managed account, without the reporting person's knowledge. One of the reported transactions resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"), and the reporting person has disgorged $374.01 to the Issuer, which amount represents all profits related to these transactions in accordance with Section 16(b). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.